Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic
- PMID: 34086984
- PMCID: PMC8212096
- DOI: 10.1111/acps.13334
Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic
Abstract
Objective: Maintenance electroconvulsive therapy (M-ECT) is considered an effective relapse prevention strategy in severe mood and psychotic disorders. How long M-ECT should be continued, and what the outcome is after its discontinuation has not been adequately studied. In our tertiary psychiatric hospital, M-ECT treatments were suspended at the start of the COVID-19 pandemic. We aimed to determine the 6-month relapse rate and time to relapse after abrupt discontinuation of M-ECT and to assess the impact of patient and treatment characteristics on the risk of relapse.
Methods: Eighty-one patients whose M-ECT was discontinued abruptly were followed up prospectively for 6 months, or until relapse (i.e., hospital admission, restart of ECT, change of pharmacotherapy, or suicide (attempt)). We used multivariable Cox proportional hazards models to assess the impact of patient and treatment characteristics on the risk of relapse.
Results: Thirty-six patients (44.44%) relapsed within 6 months following abrupt discontinuation of M-ECT. A greater number of previous acute ECT courses, a diagnosis of psychotic disorder (compared with major depressive disorder or bipolar disorder), and a shorter interval between M-ECT treatments at the time of discontinuation were significantly associated with increased risk of relapse.
Conclusion: Almost half of the patients relapsed, similar to the relapse rate after a successful acute course of ECT. Patients with a shorter interval between M-ECT treatments at the time of discontinuation seem to be at increased risk, as well as patients with a diagnosis of psychotic disorder, compared to patients with mood disorders.
Keywords: COVID-19; discontinuation; maintenance electroconvulsive therapy; relapse.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors report no conflict of interest.
Figures
Comment in
-
Electroconvulsive Therapy: Stayin' Alive, Stayin' Well.Acta Psychiatr Scand. 2021 Sep;144(3):215-217. doi: 10.1111/acps.13352. Acta Psychiatr Scand. 2021. PMID: 34397107 No abstract available.
-
How to Reliably Predict Relapse After Electroconvulsive Therapy?J Clin Psychiatry. 2021 Dec 7;83(1):21lr14269. doi: 10.4088/JCP.21lr14269. J Clin Psychiatry. 2021. PMID: 34875148 No abstract available.
References
-
- Kellner CH, Obbels J, Sienaert P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr Scand. 2020;141(4):304‐315. - PubMed
-
- Ward HB, Szabo ST, Rakesh G. Maintenance ECT in schizophrenia: A systematic review. Psychiatry Res. 2018;264:131‐142. - PubMed
-
- Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research. J ECT. 2002;18(3):149‐158. - PubMed
-
- Brown ED, Lee H, Scott D, Cummings GG. Efficacy of continuation/maintenance electroconvulsive therapy for the prevention of recurrence of a major depressive episode in adults with unipolar depression: a systematic review. J ECT. 2014;30(3):195‐202. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
